Seeking Alpha

Cell Therapeutics (CTIC +2.8%) moves higher today after publishing positive results from a...

Cell Therapeutics (CTIC +2.8%) moves higher today after publishing positive results from a pre-clinical study of Pixuvri in The Journal of Pharmacology and Experimental Therapeutics. The study showed that in a human cardiac tissue model treated with Pixuvri did not form reactive oxygen species or long lived hydroxymetabolites. Additionally, the drug inhibited formation of the long-lived hydroxymetabolite of doxorubicin, which suggests a low incidence of cardiotoxicity.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)